Another recent study confirmed the long-term physiological benefits of AAV-CRISPR therapy, indicating that genome editing and dystrophin protein restoration are maintained in the mdx mouse model of DMD for one year after a single IV administration of AAV-CRISPR editing [103]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.